Acceptability: total withdrawals · women with seizures due to catamenial epilepsy
1 finding from 1 review
no estimate extracted
24 participants
Very low
Adverse events · women with seizures due to catamenial epilepsy
1 finding from 1 review
no estimate extracted
15 participants
Very low
Quality of life · women with seizures due to catamenial epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Seizure freedom · women with seizures due to catamenial epilepsy
Progesterone showed no clear difference in seizure freedom: all seizures compared with placebo (low certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · women with seizures due to catamenial epilepsy
Progesterone showed no clear difference in responder rate: 50% or greater reduction in all seizures compared with placebo (moderate certainty).
1 finding from 1 review
Seizure frequency · women with seizures due to catamenial epilepsy
1 finding from 1 review
All‐cause mortality · people with bloodstream infections
Rapid susceptibility methods showed no clear difference in mortality compared with standard methods versus placebo (low certainty).
1 finding from 1 review
Mortality (subgroup genotypic) · people with bloodstream infections
Rapid susceptibility methods showed no clear difference in mortality (subgroup genotypic) compared with standard methods versus placebo (low certainty).
1 finding from 1 review
Mortality (subgroup phenotypic) · people with bloodstream infections
Rapid susceptibility methods showed no clear difference in mortality (subgroup phenotypic) compared with standard methods versus placebo (low certainty).
1 finding from 1 review
Mortality (with stewardship) · people with bloodstream infections
Rapid susceptibility methods showed no clear difference in mortality (with stewardship) compared with standard methods versus placebo (low certainty).
1 finding from 1 review
Mortality (without stewardship) · people with bloodstream infections
Rapid susceptibility methods showed no clear difference in mortality (without stewardship) compared with standard methods versus placebo (low certainty).
1 finding from 1 review
Time to hospital discharge · people with bloodstream infections
1 finding from 1 review
Time‐to‐appropriate antibiotic · people with bloodstream infections
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · adults (mean study ages 23 to 67 years) with acute postoperative pain after abdominal/pelvic, dental or orthopedic surgeries
It is very uncertain whether intravenous ketorolac changes number of participants with at least 50% pain relief over 4 hours compared with placebo (very low certainty).
1 finding from 1 review
Relief of pain · adults (mean study ages 23 to 67 years) with acute postoperative pain after abdominal/pelvic, dental or orthopedic surgeries
Intravenous ketorolac may leads to higher number of participants with at least 50% pain relief over 6 hours compared with placebo (low certainty).
1 finding from 1 review
Median (mean) time to use of rescue medication · adults (mean study ages 23 to 67 years) with acute postoperative pain after abdominal/pelvic, dental or orthopedic surgeries
1 finding from 1 review
Use of rescue medication · adults (mean study ages 23 to 67 years) with acute postoperative pain after abdominal/pelvic, dental or orthopedic surgeries
It is very uncertain whether intravenous ketorolac changes number of participants using rescue medication over 4 or 6 hours… compared with placebo (very low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · adults (mean study ages 23 to 67 years) with acute postoperative pain after abdominal/pelvic, dental or orthopedic surgeries
Intravenous ketorolac showed no clear difference in number of participants reporting any adverse event compared with placebo (moderate certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · adults (mean study ages 23 to 67 years) with acute postoperative pain after abdominal/pelvic, dental or orthopedic surgeries
Intravenous ketorolac showed no clear difference in number of participants experiencing a serious adverse event compared with placebo (low certainty).
1 finding from 1 review
At least 50% reduction in pain · health problem or population
It is very uncertain whether summary of Findings Table ‐ Ibuprofen changes number of participants with at least 50% pain relief at 4 hours compared with placebo (very low certainty).
2 findings from 1 review